Dose‐Response Efficacy and Safety of Factor XI/XIa Inhibitors in Atrial Fibrillation; a Systematic Review and Meta‐Analysis With Subgroup Exploration and Trial Sequential Validation
Factor XI/XIa inhibitors lower major bleeding risk in AF patients but increase stroke and systemic embolism rates without impacting mortality.
Authors
- Fatima Saeed (ORCID: https://orcid.org/0000-0002-8293-9593)
- Aqsa Khalid (ORCID: https://orcid.org/0000-0003-4973-7911)
- Jaivardhan A. Menon (ORCID: https://orcid.org/0000-0002-8332-5198)
- Moiuz Chaudhri (ORCID: https://orcid.org/0000-0003-3995-3012)
- Zainab Humayun (ORCID: https://orcid.org/0009-0007-6908-6008)
- Maria Aslam (ORCID: https://orcid.org/0000-0002-5681-4260)
- Victoria Zecchin Ferrara (ORCID: https://orcid.org/0009-0009-2948-3759)
- Muhammad Aqib Faizan (ORCID: https://orcid.org/0009-0002-6023-3992)
- Mrunalini Dandamudi (ORCID: https://orcid.org/0009-0001-3580-0783)
- Alina Tanvir
- Zeyad Kholeif
- Raheel Ahmad
- Luis Cerna
- Saad Ahmad Waqas
- Carlos Espiche
- Tooba Rehman
- Jibran Ikram
Institutions
- Brigham and Women's Hospital (US)
- George Washington University Hospital (US)
- Cleveland Clinic (US)
- Mayo Clinic (US)
- Montefiore Medical Center (US)
- Harvard University (US)
- Ayub Medical College (PK)
- University of Padua (IT)
- King Edward Medical University (PK)
- Khyber Medical University (PK)
- University of Michigan (US)
- Abbottabad University of Science and Technology (PK)
- Dow University of Health Sciences (PK)
- Massachusetts General Hospital (US)
- Women Medical College (PK)
- Michigan Medicine (US)
- Mayo Clinic in Arizona (US)
- Ocean Medical Center (US)
- Mayo Clinic in Florida (US)
- Hackensack Meridian Health (US)
- Imperial College London (GB)
- University of Missouri–Kansas City (US)
Publication Details
- Journal
- Clinical Cardiology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/clc.70263
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.00